ARTICLE | Company News
Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Jan. 16 to develop a molecular diagnostic to help stratify triple-negative breast cancer patients.
Roche will develop an assay to detect activation of RPS6KA3, which Phoenix said preliminary data suggests is present in up to 80% of TNBC patients. Phoenix said it plans to use the diagnostic in clinical trials for its lead program, PMD026, an oral small molecule RSK inhibitor that is expected to start a Phase I/Ib trial this year in TNBC patients...